Alpha 2.0
Login Register
» Articles » PMID: 2869316

Intravenous Immunoglobulin Home Treatment for Patients with Primary Immunodeficiency Diseases

Overview
Journal Lancet
Publisher Elsevier
Specialty General Medicine
Date 1986 Mar 15
PMID 2869316
Citations 13
Authors
H D Ochs
S H Fischer
M L Lee
E S Delson
H S Kingdon
R J Wedgwood
Affiliations
Soon will be listed here.
Citing Articles

Limited Innovations After More Than 65 Years of Immunoglobulin Replacement Therapy: Potential of IgA- and IgM-Enriched Formulations to Prevent Bacterial Respiratory Tract Infections.

Langereis J, van der Flier M, de Jonge M Front Immunol. 2018; 9:1925.

PMID: 30190722 PMC: 6115500. DOI: 10.3389/fimmu.2018.01925.

Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.

Heimall J, Chen J, Church J, Griffin R, Melamed I, Kleiner G J Clin Immunol. 2016; 36(6):600-9.

PMID: 27342758 DOI: 10.1007/s10875-016-0311-4.

Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.

Abolhassani H, Salehi Sadaghiani M, Aghamohammadi A, Ochs H, Rezaei N J Clin Immunol. 2012; 32(6):1180-92.

PMID: 22730009 DOI: 10.1007/s10875-012-9720-1.

Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home.

Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman C J Clin Immunol. 2006; 26(1):65-72.

PMID: 16418804 DOI: 10.1007/s10875-006-8905-x.

Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy.

Nicolay U, Haag S, Eichmann F, Herget S, Spruck D, Gardulf A Qual Life Res. 2005; 14(7):1683-91.

PMID: 16119180 DOI: 10.1007/s11136-005-1746-x.